Chart Industries Raises Funds Via Equity & Debt Offerings To Fund Howden Deal
Chart Industries Inc (NYSE:GTLS) has priced its previously announced concurrent offering of 5.9 million shares at a public offering price of…
Autolus Therapeutics’ Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise
Autolus Therapeutics plc’s (NASDAQ:AUTL) Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic…
ObsEva Approved On December 8, 2022 An Increase Of Its Share Capital Through The Issuance Of 20M Newly Registered Shares At An Issue Price Of 1/13 Of A Swiss Franc Each
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company
Reported Late Thursday, Autolus Announces Pricing Of $150M Public Offering Of 75M American Depositary Shares, Representing 75M Ordinary Shares At A Price Of $2/ADS
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten public
Reported Late Thursday, Replimune Announces Pricing Of $225M Public Offering Of 5,374,486 Shares Of Common Stock At A Price Of $23.50/Share
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering
Reported Late Thursday, Prometheus Biosciences Announces Pricing Of Public Upsized $500M Offering Of 4,545,455 Shares Of Common Stock At A Price Of $110/Share
Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion
Reported Late Thursday, Grom Social Enterprises Prices $5M Public Offering Of 1,415,682 Units At A Price Of $2.89/Unit
Grom Social Enterprises, Inc. (NASDAQ:GROM) (the "Company"), today announced the pricing of a public offering of 1,415,682 units (the "Units") at a price to the public of $2.89 per Unit and
Cabaletta Bio Announces $35 Million Offering
Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients